P. Liu

发表

Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

V. Sondak, J. Sosman, G. Weiss, 1999, Journal of Cancer Research and Clinical Oncology.

Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study.

D. Alberts, D. Moore, S. Wilczynski, 1999, Gynecologic oncology.

13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial.

D. Alberts, S. Lippman, G. Weiss, 1998, Gynecologic oncology.

A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence.

A. Roe, R. Gonzalez, S. Legha, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study.

D. Alberts, Caroline S. Jiang, R. Lavey, 2004, Gynecologic oncology.

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.

D. Alberts, C. Moinpour, G. Weiss, 2004, Gynecologic oncology.

Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial.

P. Grigsby, D. Alberts, B. Monk, 2005, Gynecologic oncology.

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.

B. Monk, S. Wilczynski, Caroline S. Jiang, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term follow‐up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

D. Alberts, S. Wilczynski, M. Rothenberg, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group

D. Alberts, S. Wilczynski, M. Rothenberg, 2003, International Journal of Gynecologic Cancer.

Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.

D. Alberts, S. Wilczynski, M. Markman, 2009, Gynecologic oncology.

Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.

D. Alberts, S. Wilczynski, S. Wadler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).

D. Alberts, G. Weiss, S. Wilczynski, 2001, Gynecologic oncology.

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.

M. Federico, D. Alberts, M. Markman, 2006, Gynecologic oncology.

Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.

G. Anderson, J. Moon, S. Wilczynski, 2009, Gynecologic oncology.

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

P. Grigsby, D. Alberts, B. Monk, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.

D. Alberts, S. Wilczynski, Caroline S. Jiang, 2005, Gynecologic oncology.

Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen.

D. Morton, R. Irie, P. Liu, 1981, Journal of the National Cancer Institute.

A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial.

D. Alberts, G. Weiss, L. Hutchins, 1992, Gynecologic oncology.

Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study.

D. Alberts, S. Wilczynski, F. Muggia, 2002, Gynecologic oncology.

Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC.

D. Alberts, B. Monk, S. Wilczynski, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.

V. Sondak, K. Kopecky, P. Liu, 1994, Anti-cancer drugs.

Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.

R. O’Toole, G. Mills, H. Gallion, 1992, Gynecologic oncology.

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508

V. Sondak, J. Sosman, J. Moon, 2010, Cancer.

Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study.

V. Sondak, S. Balcerzak, W. Samlowski, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.

V. Sondak, D. Gandara, S. Balcerzak, 1999, The cancer journal from Scientific American.

Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials.

V. Sondak, J. Unger, L. Flaherty, 1998, American journal of clinical oncology.

Evaluation of Amonafide in Cervical Cancer, Phase II: A SWOG Study

D. Alberts, P. Liu, E. Hannigan, 1992, American journal of clinical oncology.

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

N Cascinelli, J A Thompson, S J Soong, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Corynebacterium parvum and metastatic breast cancer.

C. Haskell, P. Liu, G. Sarna, 1982, British Journal of Cancer.

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).

D. Alberts, S. Wilczynski, M. Markman, 2007, Gynecologic oncology.

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

D. Alberts, R. O’Toole, S. Williams, 1996, The New England journal of medicine.

Phase III study of intraperitoneal cisplatin-intravenous cyclophosphamide versus intravenous cisplatin-intravenous cyclophosphamide in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG Intergroup study

D. Alberts, R. O’Toole, R. Alvarez, 1996, International Journal of Gynecologic Cancer.

The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).

V. Sondak, M. Walker, L. Flaherty, 1996, American journal of clinical oncology.

A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy.

D. Alberts, B. Monk, J. Moon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.

D. Alberts, B. Monk, M. Rothenberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between pretreatment CA-125 level and risk of relapse in advanced ovarian cancer (AOC) patients in a complete clinical response (CCR) who received “maintenance therapy”

D. Alberts, B. Monk, M. Brady, 2005 .

A phase 2 trial of complete resection for stage IV melanoma

V. Sondak, B. Redman, J. Sosman, 2011, Cancer.

Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.

F M Muggia, D. Alberts, R. O’Toole, 1996, Gynecologic oncology.

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.

V. Sondak, J. Sosman, G. Weiss, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Amonafide in Patients with Advanced Metastatic or Recurrent Endometrial Adenocarcinoma A Southwest Oncology Group Study

D. Alberts, R. O’Toole, J. Ward, 1994, American journal of clinical oncology.

Surgical resection for stage IV melanoma: A Southwest Oncology Group trial (S9430).

V. Sondak, B. Redman, J. Sosman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic F actors A nalysis o f 1 7,600 M elanoma P atients: Validation o f t he A merican J oint C ommittee o n C ancer Melanoma S taging S ystem

M. Ross, M. Atkins, J. Kirkwood, 2001 .

Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.

V. Sondak, J. Unger, L. Flaherty, 2002, American journal of clinical pathology.

Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.

V. Sondak, J. Unger, P Y Liu, 1997, American journal of clinical oncology.

Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035

V. Sondak, J. Sosman, J. Unger, 2004 .

Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035.

V. Sondak, J. Sosman, J. Unger, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of piroxantrone in disseminated malignant melanoma

V. Sondak, J. Sosman, J. Thompson, 2007, Investigational New Drugs.

Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study

D. Alberts, G. Weiss, M. Markman, 2004, International Journal of Gynecologic Cancer.

Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508

V. Sondak, J. Sosman, J. Moon, 2008 .

Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.

D. Alberts, E. Shpall, W. Samlowski, 2004, Gynecologic oncology.

Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.

V. Sondak, S. Balcerzak, L. Flaherty, 1992, Journal of the National Cancer Institute.

A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.

V. Sondak, J. Sosman, J. Thompson, 1995, Investigational new drugs.

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)

D. Alberts, J. Moon, S. Wilczynski, 2006, International Journal of Gynecologic Cancer.

Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study.

G. Weiss, J. Cain, J. Bickers, 1992, Investigational new drugs.

Recombinant human erythropoietin (EPO) as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a southwest oncology group study

D. Alberts, R. Lavey, M. Markman, 2003 .